Ongoing and planned trials of pharmacological agents in chronic heart failure
| Trial acronym/name* | Treatment comparisons† |
|---|---|
| *See box at end of article for explanation of trial acronyms. | |
| †New treatments tested against conventional background therapy (diuretic, digoxin, ACE inhibitor, β blocker) unless stated otherwise. | |
| ‡Recently terminated prematurely because of “futility”. | |
| ACE, angiotensin converting enzyme; LVEF, left ventricular ejection fraction. | |
| Adapted from McMurry J, Pfeffer MH. Circulation 2002;105:2099–106. | |
| Low LVEF chronic heart failure | |
| Neurohumoral antagonists | |
| CHARM Alternative | Placebo v candesartan (ACE inhibitor intolerant patients) |
| CHARM Added | Placebo v candesartan (ACE inhibitor treated patients) |
| COMET | Carvedilol v metoprolol |
| ENABLE | Placebo v bosentan |
| ECHOS | Placebo v nolomirole |
| OVERTURE | Enalapril v omapatrilat |
| SENIORS | Placebo v nebivolol (patients >70 years) |
| Cytokine antagonists | |
| RENEWAL (RECOVER‡ and RENAISSANCE) | Placebo v etanercept |
| Antithrombotic agents | |
| WATCH | Warfarin v aspirin v clopidogrel |
| Inotropic agents | |
| ESSENTIAL | Placebo v enoximone (β blocker treated patients) |
| Metabolic agents | |
| Ranolazine | Placebo v ranolazine |
| Normal LVEF congestive heart failure | |
| Neurohumoral antagonists | |
| CHARM Preserved | Placebo v candesartan |
| I-PRESERVE | Placebo v irbesartan |
| PEP-CHF | Placebo v perindopril |
| SENIORS | Placebo v nebivolol |